MedTrace Logo

Bioequivalence Study of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® 75 mg Tablet After Oral Administration to Healthy Adult Subjects Under Fasting Condition

NCT05186129 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-03-02

No results posted yet for this study

Summary

To compare the rate and extent of absorption of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® (clopidogrel) 75 mg tablet under fasting condition.

Conditions

  • Bioequivalence

Interventions

DRUG

Clopid® 75 mg Tablet

Single dose of Clopid® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.

DRUG

Plavix® 75mg Tablet

Single dose of Plavix® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.

Sponsors & Collaborators

  • Ferozsons Laboratories Ltd.

    collaborator INDUSTRY

  • Center for Bioequivalence Studies and Clinical Research

    lead OTHER

Principal Investigators

  • Dr. Muhammad R Raza, PhD · Center for Bioequivalence Studies and Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-06
Primary Completion
2018-04-15
Completion
2018-04-20

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05186129 on ClinicalTrials.gov